Cytek Biosciences Inc (CTKB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.06 is considered Undervalued compared with the five-year average of 79.65. The fair price of Cytek Biosciences Inc (CTKB) is between 22.17 to 34.11 according to relative valuation method. Compared to the current price of 4.44 USD , Cytek Biosciences Inc By Undervalued By 79.97%.

Relative Value

Fair Zone

22.17-34.11

Current Price：4.44

79.97%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cytek Biosciences Inc (CTKB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cytek Biosciences Inc (CTKB) has a current Price-to-Book (P/B) ratio of 1.66. Compared to its 3-year average P/B ratio of 2.01, the current P/B ratio is approximately -17.18% higher. Relative to its 5-year average P/B ratio of -0.15, the current P/B ratio is about -1221.59% higher. Cytek Biosciences Inc (CTKB) has a Forward Free Cash Flow (FCF) yield of approximately -0.94%. Compared to its 3-year average FCF yield of 0.86%, the current FCF yield is approximately -208.91% lower. Relative to its 5-year average FCF yield of 0.42%, the current FCF yield is about -322.72% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CTKB competitors is 60.99, providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB.O) exhibits a P/S ratio of 3.06, which is -94.97% above the industry average. Given its robust revenue growth of 8.12%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CTKB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CTKB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CTKB currently overvalued or undervalued?

What is Cytek Biosciences Inc (CTKB) fair value?

CTKB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cytek Biosciences Inc (CTKB) is between 22.17 to 34.11 according to relative valuation method.

How does CTKB's valuation metrics compare to the industry average?

The average P/S ratio for CTKB's competitors is 60.99, providing a benchmark for relative valuation. Cytek Biosciences Inc Corp (CTKB) exhibits a P/S ratio of 3.06, which is -94.97% above the industry average. Given its robust revenue growth of 8.12%, this premium appears unsustainable.

What is the current P/B ratio for Cytek Biosciences Inc (CTKB) as of Mar 04 2026?

As of Mar 04 2026, Cytek Biosciences Inc (CTKB) has a P/B ratio of 1.66. This indicates that the market values CTKB at 1.66 times its book value.

What is the current FCF Yield for Cytek Biosciences Inc (CTKB) as of Mar 04 2026?

As of Mar 04 2026, Cytek Biosciences Inc (CTKB) has a FCF Yield of -0.94%. This means that for every dollar of Cytek Biosciences Inc's market capitalization, the company generates -0.94 cents in free cash flow.

What is the current Forward P/E ratio for Cytek Biosciences Inc (CTKB) as of Mar 04 2026?

As of Mar 04 2026, Cytek Biosciences Inc (CTKB) has a Forward P/E ratio of -164.00. This means the market is willing to pay $-164.00 for every dollar of Cytek Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cytek Biosciences Inc (CTKB) as of Mar 04 2026?

As of Mar 04 2026, Cytek Biosciences Inc (CTKB) has a Forward P/S ratio of 3.06. This means the market is valuing CTKB at $3.06 for every dollar of expected revenue over the next 12 months.

CTKB Valuation